Viewing Study NCT00110357


Ignite Creation Date: 2025-12-24 @ 6:59 PM
Ignite Modification Date: 2026-02-13 @ 4:26 PM
Study NCT ID: NCT00110357
Status: COMPLETED
Last Update Posted: 2015-12-24
First Post: 2005-05-06
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors
Sponsor: Eli Lilly and Company
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Cancer View
None Refractory Solid Tumor View
Keywords: